Last updated: July 27, 2026
Troglitazone is an obsolete thiazolidinedione (TZD) with no current FDA-approved products in the U.S. after market withdrawal in 2000 due to idiosyncratic hepatotoxicity. There is no live commercial market to forecast, and “late-stage” clinical development activity is effectively historical rather than ongoing. Business impact is therefore concentrated in (1) legacy litigation and pharmacovigilance lessons for the TZD class, (2) IP and data issues tied to historical formulations and methods, and (3) clinical evidence reuse where troglitazone remains a comparator or mechanistic reference in newer TZD and diabetes programs.
What is the clinical trial history of troglitazone (Phase 1 to Phase 3 outcomes)?
Troglitazone was developed by Parke-Davis (Warner-Lambert) and later by its acquirers under a TZD mechanism that activates PPAR-gamma. The pivotal clinical dataset supported glycemic lowering in type 2 diabetes. The critical clinical finding that drove the withdrawal was severe liver injury risk, including cases of fulminant hepatic failure.
Which trials established efficacy in type 2 diabetes
Troglitazone Phase 3 programs generally evaluated:
- HbA1c reduction vs placebo and vs active comparators (including sulfonylureas and metformin in later comparisons in some protocols)
- Fasting plasma glucose and insulin sensitivity endpoints consistent with TZD class pharmacology
What safety signals ended troglitazone’s development
Troglitazone’s hepatotoxicity signal emerged as:
- Idiosyncratic liver enzyme elevations and symptomatic hepatitis
- Cases of acute liver failure requiring transplantation or resulting in death
This safety profile was not mitigated sufficiently by monitoring strategies available at the time, leading to withdrawal from the market and discontinuation of further commercialization.
Clinical “update” in practical terms
There are no active, newly reported clinical development efforts for troglitazone comparable to current standards of Phase 2/3 trial reporting. The “update” relevant to business users is that troglitazone is a historical reference drug, not a current development candidate.
Why was troglitazone withdrawn and what regulatory actions matter today?
FDA market withdrawal and label actions
Troglitazone was withdrawn in the U.S. in 2000 after reports of serious liver toxicity. This ended routine prescribing and commercialization.
EU and international status
Troglitazone also faced withdrawal and restricted availability outside the U.S., with the overarching regulatory outcome being discontinuation of marketing due to hepatotoxicity.
Regulatory consequence for current market projections
- No active U.S. NDA/ANDA commercialization status supports a forward-looking sales projection.
- Any “market” today is limited to academic citations and historical trial re-analysis rather than drug sales.
What is the Orange Book status of troglitazone?
Troglitazone is not an FDA-approved, commercially marketed prescription drug product with current Orange Book listings supporting generic competition. The regulatory status is effectively “no longer approved/marketed,” following the 2000 withdrawal.
Implication: There is no Paragraph IV generic pathway as a near-term commercial event, and no Hatch-Waxman exclusivity timeline to model.
What patents protect troglitazone and do they still matter for freedom-to-operate?
Troglitazone development and use patents are historical. Most, if not all, would have expired by now given:
- early 1990s discovery and development timelines
- long patent terms reaching beyond the current year
What “patent estate” analysis would typically cover (for completeness of legacy work)
- Composition-of-matter patents covering the active ingredient
- Formulation and dosage form patents
- Use and method-of-treatment patents in type 2 diabetes contexts
- Manufacturing process patents
Business conclusion for troglitazone
For present-day programs, troglitazone patents are not typically a gating issue for new development because the compound is not commercially active and the active-ingredient patent term would have largely run.
Are there any ongoing troglitazone clinical trials now (registry-level)?
Troglitazone is not a common active investigational agent in modern trial registries. The practical “clinical trials update” is that troglitazone is referenced as a historical TZD, with newer programs focused on safer PPAR-gamma modulators or updated TZD strategies.
Implication: there is no current clinical trial calendar driving near-term regulatory filings or adoption.
What market exists for troglitazone today and how should revenue projections be built?
Reality of current commercial demand
There is no ongoing U.S. branded sales base to project and no generic market to estimate because troglitazone is withdrawn.
Modeling approach (what to project instead of troglitazone sales)
If the objective is to quantify business impact for a portfolio:
- Use troglitazone as a risk benchmark for TZD hepatotoxicity
- Build projections around current TZD competitors (pioglitazone, rosiglitazone) or next-generation PPAR targets rather than troglitazone itself
- Treat troglitazone as a safety and regulatory case study, not as an investable revenue stream
How does troglitazone compare with pioglitazone and rosiglitazone on safety and regulatory outcomes?
Class comparison
- All TZDs carry warnings related to fluid retention and heart failure risk.
- Troglitazone uniquely had a disproportionate hepatotoxicity signal leading to withdrawal.
Competitive landscape implications
Even though troglitazone is not in market, its withdrawal altered:
- clinician and regulator tolerance for hepatotoxicity risk in TZDs
- monitoring expectations for liver enzymes
- the direction of later TZD and PPAR-gamma program development
What biosimilar or generic risk exists for troglitazone?
- Biosimilar: Not applicable. Troglitazone is a small molecule, not a biologic.
- Generic: Not applicable in the current U.S. market sense because the product is not marketed as an approved prescription drug requiring bioequivalence and product competition.
What formulation innovations were studied for troglitazone and are any still relevant?
Troglitazone was used in standard oral tablet dosing. In historical drug development, formulation and dosing strategies aimed to:
- improve exposure consistency
- support dosing convenience
- manage safety through monitoring rather than structural reformulation
No formulation innovation is associated with a current reintroduction program.
What clinical endpoints and biomarker approaches did troglitazone trials inform?
Troglitazone trials contributed to:
- clinical expectations for HbA1c reduction magnitude in type 2 diabetes
- early mechanistic linkage between insulin sensitivity improvement and glycemic outcomes
- safety monitoring practices that later programs codified, including hepatic lab surveillance norms
Key Takeaways
- Troglitazone is withdrawn and not currently FDA-approved as a marketed product in the U.S., eliminating any actionable “clinical update” tied to ongoing development or launches.
- The central clinical story is hepatotoxicity risk identified during the 1990s program, culminating in U.S. market withdrawal in 2000.
- There is no Orange Book exclusivity timeline to model and no Paragraph IV generic event to anticipate.
- “Market projection” for troglitazone itself is not viable because there is no current commercialization base.
- Troglitazone remains commercially relevant mainly as a historical efficacy and safety reference shaping TZD regulatory expectations and risk management.
FAQs
-
Is troglitazone available in any country today?
Market availability has been discontinued in major jurisdictions; any remaining access is typically limited to exceptional contexts such as legacy supply, not standard commercialization.
-
What were the main safety warnings associated with troglitazone?
Serious hepatotoxicity including hepatitis and rare acute liver failure, which drove withdrawal.
-
Could troglitazone be reintroduced as a new drug product?
Reintroduction would require a new development and regulatory pathway, but there is no current evidence of active clinical redevelopment.
-
How did troglitazone affect later TZD liver monitoring requirements?
It drove stricter attention to hepatic labs and monitoring norms in TZD prescribing practice and regulatory labeling.
-
What drugs should replace troglitazone in current market forecasts?
Forecasters should focus on currently marketed TZDs (where applicable) and competing diabetes classes rather than troglitazone.
References (APA)
- FDA. (n.d.). Drug safety communications and historical safety actions related to troglitazone withdrawal (archived FDA materials). U.S. Food and Drug Administration.
- European Medicines Agency. (n.d.). Public assessment and safety information on troglitazone (archived EMA materials). European Medicines Agency.
- Singh, S., & colleagues. (Year not specified in provided source set). Reviews on troglitazone hepatotoxicity and TZD class safety outcomes. (Source set not fully specified).
- PubMed. (n.d.). Troglitazone clinical trials and pivotal efficacy/safety publications indexed in MEDLINE. National Library of Medicine.
